Background: Nociceptin/orphanin FQ, the endogenous peptide agonist for the opioid receptor-like receptor (also known as NOP or the nociceptin receptor), has been shown to block the acquisition and expression of ethanol (EtOH)-induced conditioned place preference (CPP). Here, we report the characterization of a novel small-molecule NOP ligand AT-312 (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol) in receptor binding and GTPcS functional assays in vitro. We then investigated the effect of AT-312 on the rewarding action of EtOH in mice using the CPP paradigm. Further, using mice lacking the NOP receptor and their wild-type controls, we also examined the involvement of NOP in the effect of AT-312. Motivational effects of AT-312 alone were also assessed in the CPP paradigm.
A LCOHOLISM AND ALCOHOL-related disorders are major public health issues and place an enormous burden on society and economy (Esser et al., 2014 (Esser et al., , 2017 . When alcohol-related accidents are factored in, alcohol is among the top 3 causes of death in the United States (Mokdad et al., 2004) . Of the estimated 18 million alcoholdependent individuals in the population, only about 1 million actually receive/seek adequate treatment, which mainly involves psychosocial support in conjunction with limited pharmacotherapy. While no single medication or strategy has been shown to be very effective, it is generally accepted that having pharmacotherapy as an adjunct to behavioral interventions is the best approach for treating alcohol dependence and maintaining abstinence. For this however, the current repertoire of pharmacotherapeutic options needs to be significantly expanded. Only 3 pharmacotherapeutic agents are currently approved for the treatment of alcohol dependence in the United States, oral and intramuscular naltrexone (NTX), acamprosate, and disulfiram. Of these, NTX, an opioid receptor antagonist, has shown limited efficacy in reducing craving after stopping alcohol drinking; acamprosate, whose mechanism of action is unclear, improves abstinence rates, whereas disulfiram produces an aversive reaction to alcohol. These are still not widely adopted by physicians who treat alcohol-dependent patients, mostly due to lack of confidence about their efficacy and a range of unpleasant side effects that limit patient compliance. There still remains a need for new approaches and treatments for alcohol dependence.
Unlike other drugs of abuse, alcohol does not act at one receptor target, but dysregulates many neurotransmitter systems, ion channels, and neurocircuitry in several brain areas, particularly the ventral tegmental area, nucleus accumbens, central amygdala, and bed nucleus of stria terminalis Koob and Volkow, 2010) .
Among these, the endogenous opioid system is well known to play a key role in the rewarding and reinforcing effects of alcohol (Altshuler et al., 1980; Froehlich et al., 1990; Gianoulakis, 2004; Hubbell et al., 1986; Marfaing-Jallat et al., 1983; Weiss et al., 1990) . Indeed, as stated above, NTX, approved for use in the United States as an anti-alcohol pharmacotherapy, decreases alcohol consumption and craving in humans and decreases the rewarding properties of ethanol (EtOH) in animal models (Altshuler et al., 1980; Benjamin et al., 1993; Farren and O'Malley, 1997; Froehlich et al., 1990; Gianoulakis et al., 1996; Hubbell et al., 1991; Ji et al., 2008; Kornet et al., 1991; Marfaing-Jallat et al., 1983; Myers et al., 1986; O'Malley et al., 2002; Oslin et al., 1997; Samson and Doyle, 1985; Volpicelli et al., 1986 Volpicelli et al., , 1992 Weiss et al., 1990) . The mu, delta, and kappa opioid receptors and their respective endogenous ligands b-endorphins, enkephalins, and dynorphin have all been shown to be involved in various stages of the alcohol addiction cycle (Hall et al., 2001; Oswald and Wand, 2004; Roberts et al., 2000) .
A growing body of evidence suggests that the fourth member of the opioid receptor-ligand family, the nociceptin opioid receptor NOP (previously called the opioid receptor-like [ORL1] receptor), and its endogenous neuropeptide ligand, nociceptin/orphanin FQ (N/OFQ), are involved in alcohol reward and reinforcement (Ciccocioppo et al., 1999 (Ciccocioppo et al., , 2002 Kuzmin et al., 2003 Kuzmin et al., , 2007 . Similar to other members of the opioid receptor family, the NOP receptor is widely distributed in areas of the brain implicated in motivational behaviors as well as negative affect, such as the ventral tegmental area, nucleus accumbens, lateral hypothalamus, and the central amygdala (Neal et al., 1999a,b) . The endogenous ligand of the NOP receptor, N/OFQ, alters neurotransmitter release, particularly dopamine, GABA, and glutamate, all of which are also implicated in alcohol reward (Di Giannuario et al., 1999; Kallupi et al., 2014; Lutfy et al., 2001; Murphy et al., 1996 Murphy et al., , 2004 Sakoori and Murphy, 2004) . N/OFQ is also considered to have an "antiopioid" action in the brain (for a review, see Mogil and Pasternak, 2001 ). Exogenous administration of N/OFQ has been shown to suppress basal and drug-stimulated dopamine release in the NAc (Di Giannuario et al., 1999; Lutfy et al., 2001; Murphy et al., 1996 Murphy et al., , 2004 Sakoori and Murphy, 2004) and the rewarding properties of several common drugs of abuse (reviewed in Lutfy and Zaveri, 2016) . In particular, intracerebroventricular administration of N/OFQ has been shown to block acquisition of conditioned place preference (CPP) induced by morphine (Ciccocioppo et al., 2000; , cocaine (Sakoori and Murphy, 2004) , amphetamines (Kotlinska et al., 2003) , and alcohol (Ciccocioppo et al., 1999; Kuzmin et al., 2003 Kuzmin et al., , 2007 . A smallmolecule NOP agonist Ro 64-6198, given systemically, was also shown to block both the acquisition and expression of alcohol CPP in mice (Kuzmin et al., 2003) and alcohol selfadministration in rats (Kuzmin et al., 2007) . Another potent NOP agonist MT-7716 was shown to decrease alcohol intake in alcohol-preferring Marchigian Sardinian rats and attenuate alcohol withdrawal symptoms in alcohol-dependent Wistar rats (Ciccocioppo et al., 2014b) . Recently, SR-8993, a selective NOP agonist was reported to reduce anxiety associated with alcohol withdrawal as well as home cage and limited access alcohol drinking in Wistar rats (Aziz et al., 2016) . Interestingly, the level of N/OFQ is altered in the amygdala following restraint stress (Ciccocioppo et al., 2014a) . These studies suggest that NOP agonists may be potentially promising treatment agents for alcoholism and alcohol use disorders.
In this study, we characterized a novel small-molecule NOP ligand AT-312 (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol), for its selectivity and affinity toward the NOP and classical opioid receptors using radioligand binding assays and determined its efficacy in the [ 35 S] GTPcS functional assay conducted in Chinese hamster ovary (CHO) cells transfected with the human opioid receptors. We also determined its bioavailability and brain penetration, which showed appreciable plasma exposure and a brain-to-plasma ratio >1 after systemic (subcutaneous [s.c.]) administration in mice (Table 1) . Using this route of administration, we further determined its efficacy in reducing the rewarding action of EtOH in the CPP paradigm, a widely used animal model of drug reward (Bardo and Bevins, 2000) . To demonstrate that the effect of AT-312 in reducing alcohol CPP in mice is due to its activity at the NOP receptor, we compared its efficacy in reducing CPP induced by EtOH in mice lacking the NOP receptor and their wild-type littermates/controls. We also investigated the effect of a known NOP agonist SCH221510 on alcohol reward in this same paradigm as a control. 
MATERIALS AND METHODS

Cells
Human NOP, mu, delta, and kappa opioid receptors were individually expressed in CHO cells stably transfected with the human receptor cDNA, as we have described previously (Toll et al., 2009; Zaveri et al., 2001) . The HORL, HDOR, HKOR-FLAG19 cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, in the presence of 0.4 mg/ml G418, and 0.5% penicillin/streptomycin, in 150-mm tissue culture dishes. The HKOR-CN cells were grown in DMEM with 10% fetal bovine serum, in the presence of 0.5% penicillin/streptomycin and no G418. The HMOR cells were grown in 50% F12/DMEM with 10% fetal bovine serum, in the presence of 0.4 mg/ml G418 and 0.5% penicillin/streptomycin. Kappa-CN cells were used for KOP radioligand binding assays, while kappa-FLG19 cells were used in KOP [ 
Animals
Female mice lacking NOP (Nishi et al., 1997) and their wild-type littermates/controls (2 to 6 months old), fully backcrossed on C57BL/6J mouse strain, bred in-house, were used throughout. We used female mice because they exhibit a robust CPP response compared to male mice using the current 3-day conditioning paradigm (Nguyen et al., 2012; Tseng et al., 2013) . Mice were housed 2 to 4 per cage with free access to laboratory chow and tap water and kept under a 12-h light/12-h dark cycle in a temperature-and humiditycontrolled room. The light was on at 6 AM and off at 6 PM. All experiments were conducted during the light cycle between the hours of 10:00 AM to 5:00 PM and were performed according to the National Institutes of Health for the proper use of animals in research and approved by the Institutional Animal Care and Use Committee at Western University of Health Sciences (Pomona, CA).
Drugs
AT-312
(1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol) ( Fig. 1 ) was synthesized at Astraea Therapeutics and was of >99% chemical purity as fully characterized by nuclear magnetic resonance spectroscopy, liquid chromatographymass spectrometry, and elemental analysis. SCH221510 (Fig. 1) was purchased from Tocris Bioscience (Minneapolis, MN). These test compounds were dissolved in 1 to 2% DMSO and then diluted to the desired concentration with 0.5% aqueous hydroxypropylcellulose (HPC) and injected s.c. in a volume of 0.1 ml/10 g of body weight. Controls received 0.1 ml/10 g of body weight of the appropriate vehicle (1 to 2% DMSO in 0.5% of HPC).
In Vitro Characterization
Membrane Preparation. The cell lines are grown to confluency and then harvested for membrane preparation. The membranes are prepared in 50 mM Tris buffer (pH 7.4). Cells are scraped and centrifuged at 5009g for 12 minutes. The cell pellet is homogenized in 50 mM Tris with a Fisher Scientific PowerGen 125 rotor-stator type homogenizer, centrifuged at 20,0009g for 25 minutes, washed and recentrifuged once more at 20,0009g for 25 minutes, and aliquoted at a concentration of 3 mg/ml protein per vial and stored in a À80°C freezer till further use.
Receptor Binding. Compounds were dissolved at 10 mM stock in 100% DMSO. The assay was performed in a 96-well polystyrene plate with triplicates of 6 concentrations of each test compound (1 lM -0.01 nM), adding 100 ll of compound and 100 ll of tritiated ligands [ 12 nM for NOP). Nonspecific binding was determined using 1.0 lM of the unlabeled nociceptin for NOP, 10 lM unlabeled DAMGO for MOP, 1.0 lM unlabeled DPDPE for DOP, and 10 lM unlabeled U69,593 for KOP. Assays were initiated by addition of 800 ll of membrane per well. Samples were incubated for 60 minutes at 25°C in a total volume of 1.0 ml. In NOP receptor experiments, 1 mg/ml BSA was added to the compound dilution buffer. The incubation was terminated by rapid filtration through 0.5% PEI-soaked glass fiber filter mats (GF/C Filtermat A; PerkinElmer, Shelton, CT) on a Tomtec Mach III (Hamden, CT) cell harvester and washed 5 times with 0.5 ml of ice-cold 50 nM Tris-HCl, pH 7.4 buffer. The filters were dried overnight and soaked with scintillation cocktail before counting on a Perkin Elmer Beta plate 1205 liquid scintillation counter. Radioactivity was determined as counts per minutes (cpm). IC 50 values were determined using at least 6 concentrations of test compound and calculated using GraphPad/Prism (ISI, San Diego, CA). K i values were determined by the method of Cheng and Prusoff (1973) . GTPcS binding was conducted as we have described previously (Toll et al., 2009; Traynor and Nahorski, 1995; Zaveri et al., 2001) . Cells were scraped from tissue culture dishes into 20 mM HEPES, 1 mM EDTA, then centrifuged at 5009g for 10 minutes. Cells were resuspended in this buffer and homogenized using a Polytron Homogenizer. The homogenate was centrifuged at 27,0009g for 15 minutes, and the pellet resuspended in Buffer A, containing: 20 mM HEPES, 10 mM MgCl 2 , 100 mM NaCl, pH 7.4. The suspension was recentrifuged at 27,0009g and suspended once more in Buffer A. For the binding assay, membranes (8 to 15 lg protein) were incubated with [ 35 S]GTPcS (50 pM), GDP (10 lM), and the appropriate compound, in a total volume of 1.0 ml, for 60 minutes at 25°C. Samples were filtered over glass fiber filters and counted as described for the binding assays. Statistical analysis was conducted using Prism (ISI).
In Vivo Pharmacology
Experiment 1: To Determine the Effect of NOP Agonists on EtOH-Induced CPP. We used an unbiased CPP paradigm, widely used as an animal model of drug reward (Bardo and Bevins, 2000) , to determine the effect of AT-312 on the rewarding action of EtOH. The details of the CPP apparatus and paradigm have been provided elsewhere (Nguyen et al., 2012; Tseng et al., 2013) . Briefly, mice were tested for preconditioning place preference on day 1. On this day, mice were placed in the central neutral chamber and allowed to freely explore the conditioning chambers through this smaller central chamber. The amount of time that mice spent in each CPP chamber was recorded. On days 2 to 4, mice were conditioned with EtOH in the presence and absence of the NOP agonist. In the morning on each day, mice were treated with vehicle or one of the doses of AT-312 (1, 3 or 10 mg/kg, s.c.; n = 6 to 9 mice per group) followed, 15 minutes later, by EtOH (2 g/kg, i.p.) and then immediately confined to the drug-paired chamber (DPCh) for 15 minutes. In the afternoon, mice received vehicle followed by saline and were conditioned in the vehicle-paired chamber (VPCh). The order of conditioning was reversed for some mice to counterbalance the treatment and chamber assignment as well as the use of wild-type versus knockout mice for the morning and afternoon conditioning. Mice were then tested under a drug-free state for postconditioning place preference on day 5, as described for day 1. SCH221510 has been previously reported by Varty and colleagues (2008) as a NOP agonist. Thus, we used this compound as the control NOP agonist and determined its effect on the rewarding action of alcohol. To this end, mice were tested for preconditioning place preference on day 1, conditioned with EtOH in the presence or absence of SCH221510 (10 mg/kg) on days 2 to 4 and then tested for CPP on day 5, as described above.
Experiment 2: To Characterize the Role of the NOP Receptor in the Inhibitory Action of AT-312 on Alcohol CPP. Mice lacking NOP and their wild-type controls were tested for preconditioning place preference, received conditioning with EtOH (2 g/kg, intraperitoneal [i.p.]) in the presence or absence of AT-312 (3 mg/kg, s.c.; n = 7 mice per treatment per each genotype) on days 2 to 4, and then were tested for postconditioning place preference on day 5. On each test day, the amount of time that mice spent in the CPP chambers was recorded, as described above.
Experiment 3: To Assess the Motivational Effect of AT-312 in the Place Conditioning Paradigm. Mice were tested for baseline place preference on day 1, received conditioning on days 2 to 4, and were tested for postconditioning place preference on day 5. On each conditioning day, mice were treated with vehicle or AT-312 (3 mg/kg, s.c.; n = 5 mice per treatment) followed by saline and placed in the VPCh or DPCh. In the afternoon, mice were treated with the alternate treatment and conditioned to the opposite chamber. The amount of time that mice spent in the CPP chamber was recorded on each test day (days 1 and 5), as described above.
Experiment 4: To Determine the Effect of Pentobarbital on EtOHInduced CPP. Mice were tested for preconditioning place preference on day 1, treated with saline or pentobarbital (25 mg/kg, s.c.; n = 6 mice per treatment) 15 minutes before EtOH (2 g/kg, i.p.) on each conditioning day, and were confined to the DPCh. Animals were treated with saline 15 minutes before saline and confined to the VPCh. These treatments were given either in the morning or afternoon in a counterbalanced manner. Each conditioning session lasted for 15 minutes and was conducted on days 2 to 4. Mice were then tested for CPP on day 5, as described above.
Data Analysis
Data are presented as mean (AESEM) of the amount of time that mice spent in the DPCh or DPCh versus VPCh on preconditioning test day (day 1 [D1]) and postconditioning test day (day 5 [D5]) and were analyzed using repeated-measures 2-or 3-way analysis of variance (ANOVA). The Bonferroni's post hoc test was used to reveal significant changes between different groups. p < 0.05 was considered significant.
RESULTS
In Vitro NOP Receptor Binding Affinity and Opioid Receptor Selectivity of AT-312
The chemical structure of AT-312 is shown in Fig. 1 . The receptor binding affinity of AT-312 was determined using radioligand displacement assays conducted in membranes from CHO cells stably expressing the human NOP, MOP, DOP, and KOP receptors. As shown in Table 2 showed binding selectivity of 17-fold versus MOP, 216-fold versus KOP, and 378-fold versus DOP receptors. The NOP agonist SCH221510 tested in the same assays showed NOP binding Ki of 13.7 nM, about 40-fold lower affinity at NOP than AT-312. Also, the NOP binding affinity of SCH221510 was only 5-fold selective versus MOP, 3.6-fold versus KOP, and 29-fold versus DOP receptors. AT-312 therefore exhibits significantly higher binding affinity and selectivity for NOP compared to the positive control SCH221510. The high affinity of AT-312 for the NOP receptor is similar to that observed for other reported NOP agonists Ro 64-6198 and MT-7716 (Zaveri, 2016) .
As observed for other piperidinyl NOP ligands from our own compound library as well as those reported in the literature, AT-312 did not show appreciable affinity for the DOP receptor. Affinity profiling in a panel of 68 receptors and ion channels showed that, at a concentration of 100 nM, AT-312 did not bind to any nonopioid off-target receptors, whereas at 10 lM, it inhibited the specific binding of radioligands at the a1 adrenergic receptor by 60%, dopamine D4 receptor (86%), dopamine D3 receptor (100%), muscarinic M1 and M2 receptors (85%), NK2 receptor (92%), Ca 2+ channel (L-type) (73%) and Na+ channel (site 2) (94%), and norepinephrine transporter (65%). Overall, AT-312 appears to be a selective NOP receptor ligand.
In Vitro Functional Efficacy of AT-312
The intrinsic efficacy of AT-312 at the NOP and traditional opioid receptors was determined using the [ 35 S] GTPcS binding assay conducted in membranes of CHO cells stably transfected with the NOP and classical opioid receptors. Table 2 shows the in vitro functional efficacy profile of AT-312 and SCH221510. AT-312 is a full agonist at the NOP receptor, showing potency (EC 50 ) of 30 nM and 100% agonist stimulation compared to the endogenous NOP agonist N/OFQ. In contrast, it showed only a partial agonist efficacy of 25% at the MOP receptor and significantly lower potency compared to the MOP opioid full agonist DAMGO ( Table 2 ). AT-312 had no agonist efficacy at the KOP receptor. In these experiments, SCH221510 was also found to be a full agonist at the NOP receptor, with potency comparable to that of AT-312 (Table 2 ). However, it also showed significant agonist stimulation at the KOP receptor, in contrast to AT-312.
AT-312 Dose Dependently Blocked the Development of EtOH-Induced CPP. The novel NOP agonist AT-312 dose dependently reduced the rewarding action of EtOH (Fig. 2) . Repeated-measures ANOVA of the amount of time that mice spent in the DPCh on pre-and postconditioning days revealed a significant effect of treatment, F(3, 26) = 21.35, p < 0.01, but no effect of time, F(1, 26) = 4.48, p = 0.08, and no significant interaction between the 2 factors, F(3, 26) = 10.38, p = 0.08. The post hoc test showed that the amount of time that mice spent in the DPCh was significantly (p < 0.05) increased following EtOH conditioning in the vehicle-treated control group (Fig. 2 , compare D5 vs. D1 for the mice treated with vehicle before EtOH on conditioning days and this response was reduced by AT-312 in a dosedependent manner). In particular, the 2 higher doses of AT-312 (3 and 10 mg/kg) blocked EtOH-induced CPP [compare the amount of time between the vehicle-treated group on day 5 versus the AT-312 (3 mg/kg) group (p < 0.01) as well as against AT-312 (10 mg/kg) on this day (p < 0.001)]. Together, these results suggest that AT-312 dose dependently abolished the rewarding action of alcohol.
AT-312 Reduced the Rewarding Action of EtOH in Wild-
Type But Not in NOP Knockout Mice. The amount of time that mice lacking NOP and their wild-type littermates/controls spent in the EtOH-paired chamber on the preconditioning (D1) and postconditioning (D5) test days is shown in Fig. 3 . Three-way ANOVA revealed a significant effect of time, F(1, 1) = 26, p < 0.0001, a significant effect of context, F(1, 1) = 8.27, p < 0.01, but no effect of genotype, F(1, 1) = 1.58, p > 0.05. However, there was a significant interaction between time, context, and genotype, F(1, 1) = 6.39, p < 0.02. The post hoc test showed that conditioning with EtOH induced a significant (p < 0.05) CPP in both wild-type and knockout mice pretreated with vehicle prior to EtOH on the conditioning days, as evidenced by a significant increase in the amount of time that vehicle-treated control mice of either genotype spent in the EtOH-paired on day 5 compared to day 1 (Fig. 3, (Fig. 3 , compare NOPÀ/À treated with AT-312 group vs. vehicle-treated NOPÀ/À as well as against AT-312-treated NOP+/+ on D5). This result suggests that AT-312 exerts its inhibitory effect on the rewarding action of EtOH via the NOP receptor. AT-312 reduced locomotor activity in wild-type mice, but this response was absent in mice lacking NOP (data not shown).
AT-312 Given Alone Did Not Have Any Motivational Effect in the Place Conditioning Paradigm. Figure 4 shows the amount of time that mice, treated with vehicle in both conditioning chambers (Vehicle) and those that received vehicle in one chamber and AT-312 (3 mg/kg) in the other chamber, spent in the DPCh. Two-way ANOVA revealed no significant effect of treatment, EtOH-Induced CPP Was Reduced in Mice Treated with SCH221510, a NOP Agonist. We also determined the effect of a known NOP agonist on EtOH-induced CPP.
Considering that this compound was less selective toward the NOP receptor compared to AT-312, we determined the effect of a relatively higher dose (10 mg/kg) of this compound on the rewarding action of EtOH. Figure 5 shows the amount of time that mice treated with vehicle or the NOP agonist spent in the DPCh. Two-way repeated-measures ANOVA revealed a significant effect of time that mice spent in the EtOH-paired chamber on day 5 versus day 1, F(1, 14) = 20.44, p < 0.02, but no significant effect of treatment, F(1, 14) = 4.53, p > 0.05, and no significant interaction between the 2 factors, F(1, 14) = 3.47, p > 0.05. The Bonferroni post hoc test showed that the amount of time that mice spent in the EtOHpaired chamber was increased in vehicle-pretreated mice, suggesting that EtOH induced a significant CPP in the control group (Fig. 5 , compare the amount of time that vehicle-pretreated mice spent in the DPCh on D5 vs. D1). However, this response was reduced in mice treated with SCH221510.
Pentobarbital Reduced Motor Activity But Failed to Alter the Rewarding Action of EtOH. Figure 6 illustrates the amount of time that mice spent in the DPCh on the pre-and postconditioning test days. Three-way repeated-measures ANOVA revealed a significant effect of context (DPCh vs. VPCh; F(1, 1) = 11.61, p < 0.002) but no significant effect of time, F(1, 1) = 0.21, p > 0.05, and no significant effect of treatment, F(1, 1) = 0.50, p > 0.05. Although there was a significant context 9 time interaction, F(1, 1) = 13.40, p < 0.0001, there was no treatment 9 context, F(1, 1) = 0.001, p > 0.05, or time 9 context 9 treatment, F (1, 1) = 0.001, p > 0.05, interaction. The post hoc test showed that EtOH induced a comparable CPP response in both groups, showing that pentobarbital did not alter the rewarding action of EtOH.
Interestingly, pentobarbital induced a robust motor sedative effect and potentiated the sedative effect of alcohol on each conditioning day (data not shown).
DISCUSSION
The main findings of the present study are that the novel NOP agonist AT-312 reduced the acquisition of CPP induced by EtOH and that this effect was absent in mice lacking the NOP receptor. Similar, albeit less potent effects were also observed on alcohol reward in mice treated with the control NOP agonist SCH221510. The current results also demonstrate that AT-312 did not have motivational effects of its own at a dose (3 mg/kg) that completely abolished EtOH CPP in wild-type mice. Together, these results are consistent with previous studies with NOP agonists N/OFQ and Ro 64-6198 and confirm that NOP agonists can reduce acquisition of EtOH CPP in mice via selective action at the NOP receptor.
AT-312 is a selective and high-affinity NOP full agonist, belonging to a novel class of NOP ligands structurally unrelated to NOP agonists Ro 64-6198, MT-7716, SR-8993, and others that have shown efficacy in reducing the rewarding effects of alcohol in various animal models and paradigms (Zaveri, 2016) . A growing body of evidence suggests that NOP may be a potential target to reduce the rewarding and reinforcing actions of alcohol and other addictive drugs (see recent reviews Lutfy and Zaveri, 2016; Witkin et al., 2014; Zaveri, 2011 Zaveri, , 2016 . Consistent with existing literature, this novel NOP agonist AT-312 dose dependently reduced the rewarding action of alcohol and appeared to be more potent than the known NOP agonist, SCH221510. Although further studies are needed to define the mechanism for the greater effect of AT-312 compared to SCH221510, we speculate that it may be due to its higher affinity toward NOP. Our in vitro studies show that AT-312 exhibits at least 20-fold binding selectivity toward the NOP versus the MOP receptor and is a full agonist at NOP but a weak partial agonist at the MOP receptor, with no appreciable agonist efficacy at the KOP receptor. In comparison, SCH221510 has only a 4-fold binding selectivity versus the KOP receptor and has significant agonist efficacy at both the MOP and KOP receptors in the same assays (Table 2) . However, further studies are needed to assess the contribution of each receptor in the inhibitory effects of the 2 NOP agonists.
Considering that AT-312 displayed higher affinity for and acted as a partial agonist at the mu opioid receptor, one may argue that the inhibitory action of the drug may be due to its interaction with the MOP receptor or both receptor systems rather than NOP only. To address this issue, we used mice lacking NOP and their wild-type controls and tested whether the inhibitory effect of AT-312 is mediated via the NOP receptor. We rationalized that if AT-312 inhibits the rewarding action of alcohol via the NOP receptor, the drug would fail to alter the rewarding action of alcohol in mice lacking the NOP receptor. Consistent with this hypothesis, we observed that while the novel NOP agonist significantly reduced the rewarding action of alcohol in wild-type mice, the drug failed to alter EtOH-induced CPP in mice lacking NOP. This result suggests that AT-312 reduces the rewarding action of EtOH via the NOP receptor. However, further research is needed to assess the contribution of MOP receptor partial agonist activity in this response. Nevertheless, it is noteworthy to state that buprenorphine, a MOP partial agonist, was found to reduce alcohol consumption via its interaction with NOP (Ciccocioppo et al., 2007) and also found to reduce cocaine self-administration due to its agonist activity at the NOP and MOP receptors (Kallupi et al., 2017) .
Given that EtOH induced aversion in mice pretreated with the highest dose of AT-312 (Fig. 2) , one may argue that the NOP agonist may have reduced EtOH-induced CPP by inducing aversion. However, the lower dose of AT-312 (3 mg/kg), which also completely blocked EtOH-induced CPP in wild-type but not knockout mice (Fig. 3) , failed to induce aversion when given with alcohol (Fig. 3) or alone (Fig. 4) . This is in accord with an earlier report showing that NOP agonists may be devoid of any motivational effects (Devine et al., 1996) . Such a property could be useful to treat drug reward because the NOP agonist would not alter basal hedonic homeostasis, which may be advantageous for patient compliance and other normal daily functions.
NOP agonists are known to reduce motor activity (Devine et al., 1996) . Consistent with this, we found that AT-312 suppressed motor activity in wild-type mice and this response was absent in mice lacking NOP receptor, showing that this effect of AT-312 was also mediated via the NOP receptor. It is generally accepted that drugs that reduce locomotor activity can confound behavioral responding. This may affect the outcome of the CPP response if one tests animals in the presence of a sedative drug. However, we tested the animals for CPP in a drug-free state on the postconditioning test days and found no significant differences in locomotor activity between the vehicle-conditioned and drug-conditioned groups. Additionally, we believe that not all drugs that reduce motor activity during conditioning block the CPP response. Interestingly, alcohol is sedative in mice; yet, it induces a robust CPP response. We further demonstrated this by conducting an experiment using pentobarbital, which is a known sedative hypnotic and examined its effect on EtOH-induced CPP. While pentobarbital significantly reduced locomotor activity during conditioning, it failed to alter the CPP response on the test day (Fig. 6) , suggesting that the ability of AT-312 to reduce the rewarding action of EtOH may not be simply due to its sedative effect during conditioning.
The rewarding action of alcohol and other drugs of abuse has been linked to their ability to increase extracellular dopamine in the nucleus accumbens (Di Chiara and Imperato, 1988) . Although the mechanism of inhibitory action of AT-312 is not clear at this time, we speculate that the NOP agonist reduces the ability of alcohol to elevate extracellular dopamine levels in the nucleus accumbens. Indeed, previous studies have shown that intracerebroventricular administration of N/OFQ reduced elevation of accumbal dopamine induced by morphine (Di Giannuario et al., 1999) and cocaine (Lutfy et al., 2001; Sakoori and Murphy, 2004) . N/OFQ also attenuated the rewarding action of morphine (Ciccocioppo et al., 2000; , cocaine (Sakoori and Murphy, 2004) , and EtOH (Kuzmin et al., 2003) . Thus, we propose that the NOP agonist AT-312 reduces dopaminergic neurotransmission by acting in the ventral tegmental area and/or nucleus accumbens to reduce the rewarding action of alcohol. However, further studies are needed to identify the neuroanatomical sites of action of AT-312 in this regard.
A recent report shows that NOP receptor knockout rats exhibit reduced alcohol consumption compared to their wild-type controls although saccharin intake was not different between the rats of the 2 genotypes (Kallupi et al., 2017) . A similar reduction in EtOH self-administration was observed in rats treated with a novel orally bioavailable NOP antagonist . Interestingly, we did not observe reduced EtOH-induced CPP in mice lacking NOP although these authors found decreased EtOH selfadministration in NOP knockout rats (Kallupi et al., 2017) and in wild-type rats treated with the NOP antagonist . A parsimonious explanation of such discordant effects is that the 2 studies measured 2 different responses. Notably, Kuzmin and colleagues (2003) also found that male mice lacking N/OFQ tended to show a stronger response to EtOH. Alternately, the NOP system has been implicated in feeding, and N/OFQ has hyperphagic effects (for a review, see Witkin et al., 2014) . Thus, it is possible that food and drink consumption could be reduced in animals lacking the NOP receptor or its endogenous agonist. However, saccharin consumption was not altered in rats lacking NOP receptors (Kallupi et al., 2017) . Nevertheless, it is possible that NOP system is involved in consumption of food and drinks with caloric values and thus one would expect a difference in outcomes of the 2 studies. It is of interest to note that the novel bioavailable NOP antagonist reduced consumption of highly palatable food to the regular chow level .
Another explanation for the discrepant results could be species differences in the current and earlier studies. Interestingly, we found enhanced cocaine-induced CPP in mice lacking NOP (Marquez et al., 2008) , whereas other researchers reported reduced cocaine-induced CPP in NOP knockout rats (Kallupi et al., 2017) . The sex of animals may also have contributed to this discrepant data because we used female mice in this study. Our earlier studies have shown that female mice exhibit greater EtOH-induced CPP compared to male mice (Nguyen et al., 2012) . On the other hand, these other studies used male rats to study the role of NOP receptors in alcohol self-administration (Kallupi et al., 2017; RorickKehn et al., 2016) .
In summary, we found that a novel NOP agonist, AT-312, reduced the rewarding effects of EtOH in the CPP paradigm. The inhibitory effect of the NOP agonist was absent in NOP knockout mice, showing that the action of AT-312 was via the NOP receptor. AT-312 did not possess any motivational effects of its own at a dose that robustly reduced EtOHinduced CPP. Thus, the NOP receptor may be a potential target for the development of pharmacotherapy to treat alcohol use disorders.
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